Portal de investigação
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- D'Amico, Ferdinando
- Caron, Benedicte
- Dignass, Axel
- Jairath, Vipul
- Hart, Ailsa
- Kotze, Paulo Gustavo
- Paridaens, Kristine
- Al Awadhi, Sameer
- Kobayashi, Taku
- Siegmund, Britta
- Peyrin-Biroulet, Laurent
- Danese, Silvio
Unidades de investigação
Abstract
The i Support Therapy-Access to Rapid Treatment (iSTART) was an initiative to improve patient-centered management in mild-to-moderate ulcerative colitis (UC). Our aim was to update the iSTART recommendations in order to include fecal calprotectin (FC) in the monitoring of patients with UC and improve their management. Twelve physicians from nine countries worldwide attended a virtual international consensus meeting on 4 May 2022. Data from three systematic reviews were analyzed, and a new systematic review investigating all studies reporting measurement of FC at home was conducted. Based on literature evidence, statements were formulated, discussed, and approved by voting. Statements were considered approved if at least 75% of participants agreed with a proposed statement. Fourteen statements were approved. Based on this consensus, FC measurement should be routinely performed for monitoring patients with mild-to-moderate UC to identify disease relapses early and initiate an appropriate treatment. Further studies are needed to assess whether self-monitoring of FC is associated with better disease control and improved patients' quality of life.
Dados da publicação
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Review
- Páginas:
- -
- DOI:
- 10.3390/jcm12031142
- PubMed:
- 36769791
- Link para outro recurso:
- www.scopus.com
Journal of Clinical Medicine MDPI AG
Citações Recebidas na Web of Science: 3
Citações Recebidas na Scopus: 3
Documentos
- Não há documentos
Filiações
Keywords
- ulcerative colitis; inflammatory bowel disease; mild disease; fecal calprotectin
Projetos associados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
